KR20240144140A - Kif18a 억제제의 합성 - Google Patents

Kif18a 억제제의 합성 Download PDF

Info

Publication number
KR20240144140A
KR20240144140A KR1020247024721A KR20247024721A KR20240144140A KR 20240144140 A KR20240144140 A KR 20240144140A KR 1020247024721 A KR1020247024721 A KR 1020247024721A KR 20247024721 A KR20247024721 A KR 20247024721A KR 20240144140 A KR20240144140 A KR 20240144140A
Authority
KR
South Korea
Prior art keywords
compound
solvent
alkyl
acid
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247024721A
Other languages
English (en)
Korean (ko)
Inventor
세바스쳔 카일
다니엘 게라드 그린
마이클 토마스 코르벳
캐롤린 웨이
Original Assignee
암젠 인코포레이티드
암젠 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 인코포레이티드, 암젠 인코포레이티드 filed Critical 암젠 인코포레이티드
Publication of KR20240144140A publication Critical patent/KR20240144140A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02Sulfinic acids; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
KR1020247024721A 2022-01-26 2023-01-26 Kif18a 억제제의 합성 Pending KR20240144140A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263303470P 2022-01-26 2022-01-26
US63/303,470 2022-01-26
PCT/US2023/011636 WO2023146973A1 (en) 2022-01-26 2023-01-26 Synthesis of a kif18a inhibitor

Publications (1)

Publication Number Publication Date
KR20240144140A true KR20240144140A (ko) 2024-10-02

Family

ID=85328813

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247024721A Pending KR20240144140A (ko) 2022-01-26 2023-01-26 Kif18a 억제제의 합성

Country Status (12)

Country Link
US (1) US20250129050A1 (https=)
EP (1) EP4469437A1 (https=)
JP (1) JP2025505892A (https=)
KR (1) KR20240144140A (https=)
CN (1) CN118922406A (https=)
AR (1) AR128353A1 (https=)
AU (1) AU2023211589A1 (https=)
CA (1) CA3248925A1 (https=)
IL (1) IL314221A (https=)
MX (1) MX2024009163A (https=)
TW (1) TW202342451A (https=)
WO (1) WO2023146973A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54543A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
TW202416973A (zh) 2022-08-18 2024-05-01 美商雅客森醫療公司 Kif18a抑制劑及其用途
CN115925589A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钙盐及其制备方法
WO2025036479A1 (zh) * 2023-08-16 2025-02-20 上海湃隆生物科技有限公司 驱动蛋白kif18a抑制剂及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54543A (fr) * 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
MX2022012992A (es) * 2020-04-14 2022-11-08 Amgen Inc Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas.

Also Published As

Publication number Publication date
CN118922406A (zh) 2024-11-08
CA3248925A1 (en) 2023-08-03
JP2025505892A (ja) 2025-03-03
TW202342451A (zh) 2023-11-01
MX2024009163A (es) 2024-08-09
AR128353A1 (es) 2024-04-24
EP4469437A1 (en) 2024-12-04
WO2023146973A1 (en) 2023-08-03
IL314221A (en) 2024-09-01
US20250129050A1 (en) 2025-04-24
AU2023211589A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
KR20240144140A (ko) Kif18a 억제제의 합성
TWI475992B (zh) 製備4-{4-[({[4-氯-3-(三氯甲基)-苯基]胺基}羰基)胺基]-3-氟苯氧基}-n-甲基吡啶-2-甲醯胺、其鹽及單水合物之方法
JP7157752B2 (ja) Ag-10、その中間体及びその塩の調製方法
CN102143964A (zh) 制备腺嘌呤化合物的方法
KR20160072127A (ko) Pde4 억제제의 제조 방법
AU2020267299A1 (en) Methods of making protein deacetylase inhibitors
TW201738236A (zh) 一種製備酪胺酸激酶抑制劑及其衍生物的方法
BRPI0715831A2 (pt) processo para produÇço da 1-(3,4-diclorobenzil)-5-octilbiguanida ou um sal da mesma
EP4063351A1 (en) Preparation method of quinoline derivative compounds
EP3348554B1 (en) Method for producing triazole compound
RU2466983C2 (ru) Способ синтеза сульфонилгалогенидов и сульфонамидов из солей сульфоновых кислот
EA052216B1 (ru) Синтез ингибитора kif18a
CN111100111B (zh) 一种制备苯并噻吩衍生物的方法
AU2010299484A1 (en) Polymorphs of sorafenib acid addition salts
IL93393A (en) Process for the preparation of omicron-carboxypyridyl and omicron-carboxyquinolyl- imidazolinones
KR20160056230A (ko) 블로난세린의 제조방법 및 그를 위한 중간체
US10011567B1 (en) Method for the synthesis of acrylate derivatives
KR101278359B1 (ko) Npyy5 수용체 길항 작용을 갖는 화합물의 제조 방법 및 유용한 결정
JPH0350748B2 (https=)
KR20140027921A (ko) 디(아릴아미노)아릴 화합물의 제조 방법 및 그 합성 중간체
CN110914250B (zh) 用于合成非罗考昔的新工艺
IT202300023508A1 (it) Processo per la preparazione della forma polimorfa iii di tapinarof
DK163660B (da) Fremgangsmaade til fremstilling af benzylalkoholderivater eller farmaceutisk acceptable syreadditionssalte deraf
KR20060070566A (ko) 디페닐 에테르 화합물의 신규 제조방법
EA050035B1 (ru) Способы получения ag-10, его промежуточных соединений и их солей

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000